Paper 1
`Date: August 7, 2015
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`COALITION FOR AFFORDABLE DRUGS VII LLC,
`Petitioner,
`
`v.
`
`POZEN INC.,
`Patent Owner.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01680
`Patent 8,852,636
`
`
`
`
`
`
`
`
`PETITION FOR INTER PARTES REVIEW
`
`
`
`
`
`
`
`
`
`
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`TABLE OF CONTENTS
`
`I. 
`
`Introduction .................................................................................................... 1 
`
`II.  Mandatory Notices Per 37 C.F.R. § 42.8 ..................................................... 1 
`
`A. 
`
`B. 
`
`C. 
`
`Real Party-In-Interest ............................................................................ 1 
`
`Notice of Related Matters ..................................................................... 2 
`
`Lead and Back-Up Counsel and Service Information .......................... 3 
`
`III.  Payment of Fees ............................................................................................. 4 
`
`IV.  Requirements Per 37 C.F.R. § 42.104 .......................................................... 4 
`
`A.  Grounds for Standing ............................................................................ 4 
`
`B. 
`
`C. 
`
`D. 
`
`Identification of Challenge and Precise Relief Requested .................... 4 
`
`Evidence Relied Upon to Support the Challenge .................................. 5 
`
`The Grounds Are Not Redundant or Duplicative ................................. 5 
`
`V. 
`
`Background .................................................................................................... 6 
`
`A. 
`
`B. 
`
`C. 
`
`State of the Art ...................................................................................... 6 
`
`Prosecution History of the ’636 Patent ................................................. 8 
`
`Person of Ordinary Skill in the Art (POSA) ......................................... 9 
`
`VI.  Claim Construction ....................................................................................... 9 
`
`A. 
`
`B. 
`
`“Unit Dose Form” and “Unit Dosage Form” ........................................ 9 
`
`All Remaining Terms .......................................................................... 10 
`
`VII.  Ground 1: Goldman in view of Remington in further view of
`Lindberg Renders Obvious Claims 1-18 ................................................... 10 
`
`A.  A POSA Would Have Combined Goldman, Remington, and
`Lindberg .............................................................................................. 10 
`
`i
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`B. 
`
`Claim 1: ............................................................................................... 12 
`
`1. 
`
`2. 
`
`3. 
`
`4. 
`
`5. 
`
`6. 
`
`7. 
`
`8. 
`
`9. 
`
`A pharmaceutical composition in unit dose form suitable
`for oral administration to a patient, comprising: ...................... 13 
`
`(a) esomeprazole present in an amount effective to raise
`the gastric pH of said patient to at least 3.5 upon the
`administration of one or more of said unit dosage forms; ........ 13 
`
`(b) naproxen present in an amount effective to reduce or
`eliminate pain or inflammation in said patient upon
`administration of one or more of said unit dosage forms;
`and wherein: .............................................................................. 14 
`
`i) said unit dosage form is a tablet in which said naproxen
`is present in a core;.................................................................... 14 
`
`ii) said tablet comprises a coating, wherein said coating
`surrounds said core and does not release said naproxen
`until the pH of the surrounding medium is 3.5 or higher;
`and ............................................................................................. 15 
`
`iii) said esomeprazole is in one or more layers outside
`said core, wherein said one or more layers: .............................. 16 
`
`A) do not include an naproxen; ................................................. 16 
`
`B) are not surrounded by an enteric coating; and ..................... 17 
`
`C) upon ingestion of said tablet by a patient, release said
`esomeprazole into said patient’s stomach. ................................ 17 
`
`C. 
`
`D. 
`
`E. 
`
`Claim 2: The pharmaceutical composition of claim 1, wherein
`there is a single core comprising said naproxen. ................................ 18 
`
`Claim 3: The pharmaceutical composition of claim 2, wherein
`said esomeprazole is present in said unit dosage form in an
`amount of between 5 mg and 100 mg. ................................................ 18 
`
`Claim 4: The pharmaceutical composition of claim 2, wherein
`naproxen is present in said unit dosage form in an amount of
`
`ii
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`200-600 mg. ......................................................................................... 19 
`
`F. 
`
`G. 
`
`Claim 5: A method of treating a patient for pain or
`inflammation, comprising administering to said patient a
`therapeutically effective amount of the pharmaceutical
`composition of claim 1. ....................................................................... 20 
`
`Claim 6: The method of claim 5, wherein said pain or
`inflammation is due to either osteoarthritis or rheumatoid
`arthritis. ................................................................................................ 20 
`
`H. 
`
`Claim 7: ............................................................................................... 21 
`
`1. 
`
`2. 
`
`3. 
`
`4. 
`
`5. 
`
`6. 
`
`7. 
`
`8. 
`
`9. 
`
`A pharmaceutical composition in unit dose form suitable
`for oral administration to a patient, comprising: ...................... 21 
`
`(a) esomeprazole present in an amount effective to raise
`the gastric pH of said patient to at least 3.5 upon the
`administration of one or more of said unit dosage forms; ........ 21 
`
`(b) naproxen present in an amount effective to reduce or
`eliminate pain or inflammation in said patient upon
`administration of one or more of said unit dosage forms;
`and wherein: .............................................................................. 22 
`
`i) said unit dosage form is a capsule in which said
`naproxen is present in a core; .................................................... 23 
`
`ii) said capsule comprises a coating, wherein said coating
`surrounds said core containing said naproxen and does
`not release said naproxen until the pH of the surrounding
`medium is 3.5 or higher; and .................................................... 24 
`
`iii) said esomeprazole is in one or more layers outside
`said core, wherein said one or more layers: .............................. 25 
`
`A) do not include an naproxen; ................................................. 26 
`
`B) are not surrounded by an enteric coating; and ..................... 26 
`
`C) upon ingestion of said capsule by a patient, release
`
`iii
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`I. 
`
`J. 
`
`K. 
`
`L. 
`
`said esomeprazole into said patient’s stomach. ........................ 27 
`
`Claim 8: The pharmaceutical composition of claim 7, wherein
`there are multiple particles of said naproxen each constituting a
`core surrounded by said coating that does not release said
`naproxen until the pH of the surrounding medium is 3.5 or
`higher. .................................................................................................. 27 
`
`Claim 9: The pharmaceutical composition of claim 8, wherein
`said esomeprazole is present in said unit dosage form in an
`amount of between 5 mg and 100 mg. ................................................ 29 
`
`Claim 10: The pharmaceutical composition of claim 8, wherein
`naproxen is present in said unit dosage form in an amount of
`200-600 mg. ......................................................................................... 30 
`
`Claim 11: A method of treating a patient for pain or
`inflammation, comprising administering to said patient a
`therapeutically effective amount of the pharmaceutical
`composition of claim 7. ....................................................................... 30 
`
`M.  Claim 12: The method of claim 11, wherein said pain or
`inflammation is due to either osteoarthritis or rheumatoid
`arthritis. ................................................................................................ 31 
`
`N. 
`
`O. 
`
`P. 
`
`Q. 
`
`Claim 13: The pharmaceutical composition of claim 1, further
`comprising at least one carrier. ........................................................... 31 
`
`Claim 14: The pharmaceutical composition of claim 1, further
`comprising at least one auxiliary agent chosen from the group
`consisting of lubricants, preservatives, disintegrants, stabilizers,
`wetting agents, emulsifiers, salts, buffers, coloring agents,
`flavoring agents, and aromatic substances. ......................................... 32 
`
`Claim 15: The pharmaceutical composition of claim 1, further
`comprising at least one ingredient to adjust pH. ................................. 32 
`
`Claim 16: The pharmaceutical composition of claim 7, further
`comprising at least one carrier. ........................................................... 33 
`
`iv
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`R. 
`
`Claim 17: The pharmaceutical composition of claim 7, further
`comprising at least one auxiliary agent chosen from the group
`consisting of lubricants, preservatives, disintegrants, stabilizers,
`wetting agents, emulsifiers, salts, buffers, coloring agents,
`flavoring agents, and aromatic substances. ......................................... 33 
`
`S. 
`
`Claim 18: The pharmaceutical composition of claim 7, further
`comprising at least one ingredient to adjust pH. ................................. 34 
`
`VIII.  Ground 2: Gimet in view of Goldman and Lindberg Renders
`Obvious Claims 1-6 and 13-15 .................................................................... 34 
`
`A.  A POSA Would Have Combined Gimet, Goldman, and
`Lindberg .............................................................................................. 34 
`
`B. 
`
`Claim 1: ............................................................................................... 37 
`
`1. 
`
`2. 
`
`3. 
`
`4. 
`
`5. 
`
`6. 
`
`7. 
`
`A pharmaceutical composition in unit dose form suitable
`for oral administration to a patient, comprising: ...................... 37 
`
`(a) esomeprazole present in an amount effective to raise
`the gastric pH of said patient to at least 3.5 upon the
`administration of one or more of said unit dosage forms; ........ 37 
`
`(b) naproxen present in an amount effective to reduce or
`eliminate pain or inflammation in said patient upon
`administration of one or more of said unit dosage forms;
`and wherein: .............................................................................. 38 
`
`i) said unit dosage form is a tablet in which said naproxen
`is present in a core;.................................................................... 40 
`
`ii) said tablet comprises a coating, wherein said coating
`surrounds said core and does not release said naproxen
`until the pH of the surrounding medium is 3.5 or higher;
`and ............................................................................................. 40 
`
`iii) said esomeprazole is in one or more layers outside
`said core, wherein said one or more layers: .............................. 41 
`
`A) do not include an naproxen; ................................................. 41 
`
`v
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`C. 
`
`D. 
`
`E. 
`
`F. 
`
`G. 
`
`H. 
`
`I. 
`
`8. 
`
`9. 
`
`B) are not surrounded by an enteric coating; and ..................... 42 
`
`C) upon ingestion of said tablet by a patient, release said
`esomeprazole into said patient’s stomach. ................................ 42 
`
`Claim 2: The pharmaceutical composition of claim 1, wherein
`there is a single core comprising said naproxen. ................................ 43 
`
`Claim 3: The pharmaceutical composition of claim 2, wherein
`said esomeprazole is present in said unit dosage form in an
`amount of between 5 mg and 100 mg. ................................................ 43 
`
`Claim 4: The pharmaceutical composition of claim 2, wherein
`naproxen is present in said unit dosage form in an amount of
`200-600 mg. ......................................................................................... 44 
`
`Claim 5: A method of treating a patient for pain or
`inflammation, comprising administering to said patient a
`therapeutically effective amount of the pharmaceutical
`composition of claim 1. ....................................................................... 45 
`
`Claim 6: The method of claim 5, wherein said pain or
`inflammation is due to either osteoarthritis or rheumatoid
`arthritis. ................................................................................................ 45 
`
`Claim 13: The pharmaceutical composition of claim 1, further
`comprising at least one carrier. ........................................................... 46 
`
`Claim 14: The pharmaceutical composition of claim 1, further
`comprising at least one auxiliary agent chosen from the group
`consisting of lubricants, preservatives, disintegrants, stabilizers,
`wetting agents, emulsifiers, salts, buffers, coloring agents,
`flavoring agents, and aromatic substances. ......................................... 46 
`
`J. 
`
`Claim 15: The pharmaceutical composition of claim 1, further
`comprising at least one ingredient to adjust pH. ................................. 47 
`
`IX.  Ground 3: Ouali in view of Lindberg Renders Obvious Claims 7-
`12 and 16-18 .................................................................................................. 47 
`
`A.  A POSA Would Have Combined Ouali and Lindberg ....................... 47 
`
`vi
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`A. 
`
`Claim 7: ............................................................................................... 49 
`
`1. 
`
`2. 
`
`3. 
`
`4. 
`
`5. 
`
`6. 
`
`7. 
`
`8. 
`
`9. 
`
`A pharmaceutical composition in unit dose form suitable
`for oral administration to a patient, comprising: ...................... 49 
`
`(a) esomeprazole present in an amount effective to raise
`the gastric pH of said patient to at least 3.5 upon the
`administration of one or more of said unit dosage forms; ........ 49 
`
`(b) naproxen present in an amount effective to reduce or
`eliminate pain or inflammation in said patient upon
`administration of one or more of said unit dosage forms;
`and wherein: .............................................................................. 51 
`
`i) said unit dosage form is a capsule in which said
`naproxen is present in a core; .................................................... 51 
`
`ii) said capsule comprises a coating, wherein said coating
`surrounds said core containing said naproxen and does
`not release said naproxen until the pH of the surrounding
`medium is 3.5 or higher; and .................................................... 52 
`
`iii) said esomeprazole is in one or more layers outside
`said core, wherein said one or more layers: .............................. 53 
`
`A) do not include an naproxen; ................................................. 54 
`
`B) are not surrounded by an enteric coating; and ..................... 54 
`
`C) upon ingestion of said capsule by a patient, release
`said esomeprazole into said patient’s stomach. ........................ 55 
`
`B. 
`
`C. 
`
`Claim 8: The pharmaceutical composition of claim 7, wherein
`there are multiple particles of said naproxen each constituting a
`core surrounded by said coating that does not release said
`naproxen until the pH of the surrounding medium is 3.5 or
`higher. .................................................................................................. 56 
`
`Claim 9: The pharmaceutical composition of claim 8, wherein
`said esomeprazole is present in said unit dosage form in an
`amount of between 5 mg and 100 mg. ................................................ 57 
`
`vii
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`D. 
`
`E. 
`
`F. 
`
`G. 
`
`H. 
`
`Claim 10: The pharmaceutical composition of claim 8, wherein
`naproxen is present in said unit dosage form in an amount of
`200-600 mg. ......................................................................................... 58 
`
`Claim 11: A method of treating a patient for pain or
`inflammation, comprising administering to said patient a
`therapeutically effective amount of the pharmaceutical
`composition of claim 7. ....................................................................... 58 
`
`Claim 12: The method of claim 11, wherein said pain or
`inflammation is due to either osteoarthritis or rheumatoid
`arthritis. ................................................................................................ 59 
`
`Claim 16: The pharmaceutical composition of claim 7, further
`comprising at least one carrier. ........................................................... 59 
`
`Claim 17: The pharmaceutical composition of claim 7, further
`comprising at least one auxiliary agent chosen from the group
`consisting of lubricants, preservatives, disintegrants, stabilizers,
`wetting agents, emulsifiers, salts, buffers, coloring agents,
`flavoring agents, and aromatic substances. ......................................... 60 
`
`I. 
`
`Claim 18: The pharmaceutical composition of claim 7, further
`comprising at least one ingredient to adjust pH. ................................. 60 
`
`X.  Any Secondary Considerations of Nonobviousness Would Fail ............. 60 
`
`XI.  Conclusion .................................................................................................... 60 
`
`
`
`
`
`viii
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`TABLE OF AUTHORITIES
`
`Cases 
`
`Iron Dome LLC v. Chinook Licensing DE LLC,
`IPR2014-00674, Paper 9 (Sept. 10, 2014) ............................................................. 4
`
`Statutes 
`
`35 U.S.C. § 102(a) ..................................................................................................... 5
`
`35 U.S.C. § 102(b) ..................................................................................................... 5
`
`35 U.S.C. § 102(e) ..................................................................................................... 5
`
`35 U.S.C. § 311(a) ..................................................................................................... 4
`
`35 U.S.C. §§ 311-319 ................................................................................................ 1
`
`Regulations 
`
`37 C.F.R. § 42.10(b) .................................................................................................. 4
`
`37 C.F.R. § 42.100 et seq. .......................................................................................... 1
`
`37 C.F.R. § 42.100(b) .............................................................................................. 10
`
`37 C.F.R. § 42.104 ..................................................................................................... 4
`
`37 C.F.R. § 42.15(a) ................................................................................................... 4
`
`37 C.F.R. § 42.6(c) ..................................................................................................... 5
`
`37 C.F.R. § 42.63(e) ................................................................................................... 5
`
`37 C.F.R. § 42.8 ......................................................................................................... 1
`
`ix
`
`

`

`IPR2015-01680IPR2015-01680
`
`
`
`IPR2015-01680
`Patent 8,852,636
`
`Patent 8,852,636Patent 8,852,636
`
`
`37 C.F.R. § 42.8(b)(1) ................................................................................................ 1
`
`37 C.F.R. § 42.8(b)(1) ................................................................................................ 137 C.F.R. § 42.8(b)(1) ................................................................................................ 1
`
`37 C.F.R. § 42.8(b)(2) ................................................................................................ 2
`
`37 C.F.R. § 42.8(b)(2) ................................................................................................ 237 C.F.R. § 42.8(b)(2) ................................................................................................ 2
`
`37 C.F.R. § 42.8(b)(3) ................................................................................................ 3
`
`37 C.F.R. § 42.8(b)(3) ................................................................................................ 337 C.F.R. § 42.8(b)(3) ................................................................................................ 3
`
`37 C.F.R. § 42.8(b)(4) ................................................................................................ 3
`
`37 C.F.R. § 42.8(b)(4) ................................................................................................ 337 C.F.R. § 42.8(b)(4) ................................................................................................ 3
`
`
`
`
`
`x
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`EXHIBIT LIST
`
`Exhibit No. Description
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`1014
`
`1015
`
`U.S. Patent No. 8,852,636 (“the ’636 Patent”)
`
`File History of the ’636 Patent, U.S. Patent App. No. 14/045,156
`(“the ’156 Application”)
`
`Declaration of Leon Shargel, Ph.D., R.Ph.
`
`U.S. Patent No. 5,204,118 (“Goldman”)
`
`“Remington’s Pharmaceutical Sciences,” Alfonso R. Gennaro, et
`al., Mack Publ’g Co., Seventeenth Edition, (1985) (“Remington”)
`
`U.S. Patent No. 5,698,225 (“Gimet”)
`
`U.S. Patent No. 5,714,504 (“Lindberg”)
`
`U.S. Patent No. 6,183,779 (“Ouali”)
`
`U.S. Patent No. 6,926,907 (“the ’907 Patent”)
`
`Certificate of Correction for the ’907 Patent (December 25, 2007)
`
`“Esomeprazole Provides Improved Acid Control vs. Omeprazole in
`Patients with Symptoms of Gastro-Oesophageal Reflux Disease,”
`T. Lind, et al., Alimentary Pharmacology & Therapeutics, Vol. 14,
`Issue 7 (July 2000) (“Lind”)
`
`U.S. Patent No. 4,757,060
`
`“The Mechanism of Action of Aspirin,” J.R. Vane, et al., Pergamon
`(June 15, 2003)
`
`G.B. Patent No. 1211134
`
`“Drug-Induced Peptic Ulcer Disease,” Valerie Vella, Journal of the
`Malta College of Pharmacy Practice, Issue 10 (2005)
`
`xi
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`Exhibit No. Description
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`“Goodman & Gilman’s The Pharmacological Basis of
`Therapeutics,” Joel G. Hardman, et al., McGraw-Hill Publ’g Co.,
`Ninth Edition (1996)
`
`“Upper Gastrointestinal (GI) pH in Young, Healthy Men and
`Women,” Jennifer B. Dressman, et al., Pharmaceutical Research,
`Vol. 7, No. 7 (July 1990)
`
`“Effect of Orally Administered Prostaglandin E2 and its 15-Methyl
`Analogues on Gastric Secretion,” S. M. M. Karim, et al., British
`Med. Journal (Jan. 20, 1973)
`
`“Tagamet: The Discovery of Histamine H2-Receptor Antagonists,”
`SmithKlein Beecham Pharm., Am. Chem. Soc. (Nov. 24, 1997)
`“Inhibition of Gastric (H+ + K+)-ATPase by the Substituted
`Benzimidazole Picoprazole,” B. Wallmark, et al., Biochimica et
`Biophysica Acta, Vol. 728, Issue 1 (Sept. 2, 1983)
`
`U.S. Patent No. 4,255,431
`
`Notice of Final Determination, In re: Patent Term Extension for
`U.S. Patent No. 6,143,771 (July 28, 2005)
`
`“Drug Discovery: Practices, Processes, and Perspectives,” Jie Jack
`Li, et al., John Wiley & Sons (Apr. 3, 2013)
`
`“Prevention of the Gastrointestinal Adverse Effects of Nonsteroidal
`Anti-Inflammatory Drugs,” Gregor J.E. Brown, et al., Drug Safety,
`Vol. 21, Issue 6 (Dec. 21, 1999)
`
`U.S. Patent App. Pub. No. 2002/0045184 (“Chen”)
`
`“Management of NSAID-Related Gastrointestinal Mucosal Injury,”
`Adam F. Barrison, et al., Inflammopharmacology, Vol. 7, No. 3
`(Sept. 1999)
`
`xii
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`Exhibit No. Description
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`“Prevention of NSAID-Induced Gastroduodenal Ulcers,” A.
`Rostom, et al., Cochrane Database of Systematic Reviews, Issue 4
`(2002)
`
`“Abolition by Omeprazole of Aspirin Induced Gastric Mucosal
`Injury in Man,” T. K. Daneshmend, et al., Gut, Vol. 31, Issue 5
`(May 1990)
`
`U.S. Patent No. 6,319,519
`
`U.S. Patent No. 6,365,184 (“Depui”)
`VIMOVO® (Naproxen and Esomeprazole Magnesium) Tablets,
`Horizon Pharma, http://www.horizonpharma.com/vimovo/ (last
`visited May 9, 2015)
`
`Horizon Pharma plc 2014 Irish Statutory Accounts, Horizon
`Pharma Public Limited Company (Apr. 9, 2015)
`
`Shargel Walmart Receipts
`
`Int’l Patent Pub. No. WO 98/54171
`
`U.S. Patent No. 6,262,085
`
`U.S. Patent Pub. No. 2001/0000468
`
`U.S. Patent No. 5,051,262
`
`“Effects of Misoprostol on Gastric Acid and Mucus Secretion in
`Man,” Donald E. Wilson, et al., Digestive Diseases and Sciences,
`Vol. 31, No. 2 (Feb. 1986)
`
`“Measurement of Gastrointestinal pH Profiles in Normal Ambulant
`Human Subjects,” D. F. Evans, et al., Gut, Vol. 29, Issue 8 (Aug.
`1988) (“Evans”)
`
`xiii
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`
`Exhibit No. Description
`
`1040
`
`1041
`
`1042
`
`1043
`
`1044
`
`1045
`
`1046
`
`“Omeprazole,” Stephen P. Clissold, et al., Drugs, Vol. 32, Issue 1
`(July 1986) (“Clissold”)
`
`“Development of an Oral Formulation of Omeprazole,” A. Pilbrant,
`Scandinavian Journal of Gastroenterology, Vol. 20, No. s108
`(1985) (“Pilbrant”)
`
`“Effects of Single and Repeated Doses of Omeprazole on Gastric
`Acid and Pepsin Secretion in Man,” C. W. Howden, et al., Gut,
`Vol. 25, Issue 7 (July 1984) (“Howden”)
`
`“Omeprazole: A Study of Its Inhibition of Gastric pH and Oral
`Pharmacokinetics After Morning or Evening Dosage,” Peter J.
`Prichard, et al., Gastroenterology, Vol. 88, Issue 1, Part 1 (Jan.
`1985) (“Prichard”)
`
`“The Effects of Oral Doses of Lansoprazole and Omeprazole on
`Gastric pH,” Keith G. Tolman, et al., Journal of Clinical
`Gastroenterology, Vol. 24, Issue 2 (Mar. 1997) (“Tolman”)
`
`Citizen Petition, Horizon Pharma (Feb. 3, 2014)
`
`“Clinical Trial: Evaluation of Gastric Acid Suppression with Three
`Doses of Immediate-Release Esomeprazole in the Fixed-Dose
`Combination of PN 400 (Naproxen/Esomeprazole Magnesium)
`Compared with Naproxen 500 mg and Enteric-Coated
`Esomeprazole 20 mg: A Randomized, Open-Label, Phase I Study
`in Healthy Volunteers,” P. Miner, Jr., et al., Alimentary
`Pharmacology & Therapeutics, Vol. 32, Issue 3 (Aug. 2010)
`(“Miner”)
`
`1047
`
`FDA Response to Horizon’s Citizen Petition (July 3, 2014)
`
`
`
`xiv
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`I.
`
`Introduction
`
`The Coalition for Affordable Drugs VII LLC (“CFAD” or “Petitioner”)
`
`respectfully requests inter partes review of claims 1-18 of U.S. Patent No.
`
`8,852,636 (“the ’636 Patent”) (Ex. 1001) in accordance with 35 U.S.C. §§ 311-319
`
`and 37 C.F.R. § 42.100 et seq. The ’636 Patent is assigned to Pozen Inc.
`
`II. Mandatory Notices Per 37 C.F.R. § 42.8
`A. Real Party-In-Interest
`Pursuant to 37 C.F.R. § 42.8(b)(1), CFAD certifies that Coalition For
`
`Affordable Drugs VII LLC; Hayman Credes Master Fund, L.P. (“Credes”);
`
`Hayman Orange Fund SPC – Portfolio A (“HOF”); Hayman Capital Master Fund,
`
`L.P. (“HCMF”); Hayman Capital Management, L.P. (“HCM”); Hayman Offshore
`
`Management, Inc. (“HOM”); Hayman Investments, L.L.C. (“HI”); nXn Partners,
`
`LLC (“nXnP”); IP Navigation Group, LLC (“IPNav”); J Kyle Bass; and Erich
`
`Spangenberg (collectively, “RPI”) are the real parties-in-interest. The RPI certify
`
`the following: CFAD is a wholly owned subsidiary of Credes. Credes is a limited
`
`partnership. HOF is a segregated portfolio company. HCMF is a limited
`
`partnership. HCM is the general partner and investment manager of Credes and
`
`HCMF. HCM is the investment manager of HOF. HOM is the administrative
`
`general partner of Credes and HCMF. HI is the general partner of HCM. J Kyle
`
`Bass is the sole member of HI and sole shareholder of HOM. CFAD, Credes,
`
`1
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`HOF, and HCMF act, directly or indirectly, through HCM as the general partner
`
`and/or investment manager of Credes, HOF, and HCMF. nXnP is a paid
`
`consultant to HCM. Erich Spangenberg is the Manager and majority member of
`
`nXnP. IPNav is a paid consultant to nXnP. Erich Spangenberg is the Manager and
`
`majority member of IPNav. Other than HCM and J Kyle Bass in his capacity as
`
`the Chief Investment Officer of HCM and nXnP and Erich Spangenberg in his
`
`capacity as the Manager/CEO of nXnP, no other person (including any investor,
`
`limited partner, or member or any other person in any of CFAD, Credes, HOF,
`
`HCMF, HCM, HOM, HI, nXnP, or IPNav) has authority to direct or control (i) the
`
`timing of, filing of, content of, or any decisions or other activities relating to this
`
`petition or (ii) any timing, future filings, content of, or any decisions or other
`
`activities relating to the future proceedings related to this petition. All of the costs
`
`associated with this petition are expected to be borne by HCM, CFAD, Credes,
`
`HOF, and/or HCMF.
`
`B. Notice of Related Matters
`Per 37 C.F.R. § 42.8(b)(2), CFAD is aware of the following judicial matters
`
`involving the ’636 Patent: (1) Horizon Pharma, Inc. v. Actavis Labs. FL, Inc.,
`
`3:15-cv-03322 (D.N.J.); (2) Horizon Pharma, Inc. v. Dr. Reddy’s Labs., Inc., 3:15-
`
`cv-03324 (D.N.J.); (3) Horizon Pharma, Inc. v. Lupin Ltd., 3:15-cv-03326
`
`(D.N.J.); and (4) Horizon Pharma, Inc., v. Mylan Pharmas., Inc. 3:15-cv-03327
`
`2
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`(D.N.J.). In addition, CFAD is aware of the following judicial and administrative
`
`matters involving patents related to the ’636 Patent: (1) AstraZeneca AB v. Dr.
`
`Reddy’s Labs. Inc., 3:11-cv-02317 (D.N.J.); (2) AstraZeneca AB v. Dr. Reddy’s
`
`Labs., Inc., 3:13-cv-00091 (D.N.J.); (3) AstraZeneca AB v. Watson Labs., Inc.-
`
`Florida, 3:13-cv-03038 (D.N.J.); (4) AstraZeneca AB v. Mylan Pharmas., 3:13-cv-
`
`04022 (D.N.J.); (5) Dr. Reddy’s Labs., Inc. v. Pozen Inc., IPR2015-00802
`
`(P.T.A.B.); (6) Coalition for Affordable Drugs VII LLC v. Pozen Inc., IPR2015-
`
`01241 (P.T.A.B.); and (7) Coalition for Affordable Drugs VII LLC v. Pozen Inc.,
`
`IPR2015-01344 (P.T.A.B.).
`
`C. Lead and Back-Up Counsel and Service Information
`Per 37 C.F.R. § 42.8(b)(3), CFAD designates counsel as follows:
`
`Lead Counsel
`Amy E. LaValle (Reg. No. 51,092)
`alavalle@conleyrose.com
`Postal and Hand-Delivery Address:
`Conley Rose, P.C.
`5601 Granite Parkway, Suite 500
`Plano, Texas 75024
`(972) 731-2288 (phone)
`(972) 731-2289 (fax)
`
`Back-Up Counsel
`Jerry C. Harris, Jr. (Reg. No.
`66,822)
`jcharris@conleyrose.com
`Rodney B. Carroll (Reg. No.
`39,624)
`rcarroll@conleyrose.com
`Postal and Hand-Delivery Address:
`Conley Rose, P.C.
`5601 Granite Parkway, Suite 500
`Plano, Texas 75024
`(972) 731-2288 (phone)
`(972) 731-2289 (fax)
`
`
`Per 37 C.F.R. § 42.8(b)(4), CFAD may be served at the above addresses for Lead
`
`and Back-Up Counsel. CFAD consents to electronic service by e-mail. Per 37
`
`3
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`C.F.R. § 42.10(b), a Power of Attorney accompanies this Petition.
`
`III. Payment of Fees
`The undersigned authorizes the Office to charge the fee required by
`
`37 C.F.R. § 42.15(a) for this Petition to Deposit Account No. 50-1515.
`
`IV. Requirements Per 37 C.F.R. § 42.104
`A. Grounds for Standing
`CFAD certifies that the ’636 Patent is available for inter partes review and
`
`that CFAD is not barred or estopped from requesting inter partes review
`
`challenging claims 1-18 of the ’636 Patent on the grounds identified in this
`
`Petition. Pursuant to 35 U.S.C. § 311(a), any person or entity, including CFAD,
`
`“who is not the owner of a patent may file with the Office a petition to institute an
`
`inter partes review of the patent.” See Iron Dome LLC v. Chinook Licensing DE
`
`LLC, IPR2014-00674, Paper 9 (Sept. 10, 2014) (allowing petition filed by third
`
`party with no relationship to any parties to lawsuits involving patent owner to
`
`proceed on the merits). Accordingly, CFAD has standing and is entitled to petition
`
`the PTAB for review of the ’636 Patent.
`
`B.
`Identification of Challenge and Precise Relief Requested
`Ground 1: CFAD challenges claims 1-18 of the ’636 Patent and seeks a
`
`ruling that those claims are unpatentable under 35 U.S.C. § 103(a) as obvious over
`
`Goldman (Ex. 1004) in view of Remington (Ex. 1005) and in further view of
`
`4
`
`

`

`IPR2015-01680
`Patent 8,852,636
`
`Lindberg (Ex. 1007). Goldman, Remington, and Lindberg are available as prior art
`
`under 35 U.S.C. § 102(b).
`
`Ground 2: CFAD challenges c